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ABsTRAcT
Heterozygous mutations in the transcription factor gene p63 are causative for several 
syndromes with ectodermal dysplasia, orofacial clefting and limb malformations as the 
key characteristics. Different combinations of these features are seen in five different 
syndromes, of which ectrodactyly, ectodermal dysplasia and cleft lip/palate syndrome 
(EEC) is the most common one. Mutations in p63 can also cause non-syndromic single 
malformations, such as split hand foot malformation (SHFM4) and isolated cleft lip 
(NSCL). In this article we will present an overview of diseases caused by mutations in the 





hand/foot	malformation	and	orofacial	 clefting.3-7	Mutations	 in	 the	p63	 gene	 can	cause	
at	 least	 five	 different	 syndromes:	 ectrodactyly,	 ectodermal	 dysplasia	 and	 cleft	 lip/palate	
syndrome	 (EEC,	 OMIM	 604292),	 ankyloblepharon-ectodermal	 defects-cleft	 lip/palate	
syndrome	 (AEC,	 OMIM	 106260),	 limb	 lammary	 syndrome	 (LMS,	 OMIM	 603543),	
acro-dermato-ungual-lacrimal-tooth	 syndrome	 (ADULT,	 OMIM	 103285)	 and	 Rapp-
Hodgkin	 syndrome	 (RHS,	OMIM	129400).	Furthermore,	 two	non-syndromic	human	
disorders	are	caused	by	p63	mutations:	 isolated	split	hand/foot	malformation	(SHFM4,	
OMIM	 605289)	 and	 recently	 non-syndromic	 cleft	 lip.8	 Here	 we	 present	 an	 overview	



























Split	 hand/foot	 malformation	 (SHFM)	 constitutes	 the	 second	







The	 third	 hallmark	 of	 p63	 syndrome	 phenotype	 is	 orofacial	
clefting	(Fig.	1).	It	is	mainly	seen	in	the	form	of	cleft	lip	(CL)	and/
or	cleft	palate	 (CP).	This	 symptom	is	usually	observed	as	part	of	a	
complex	 syndrome,	 where	 other	 organs	 are	 also	 affected,	 however,	
recently	 Leoyklang	 et	 al.8	 have	 described	 mutations	 in	 p63	 gene	
causing	orofacial	clefting	as	the	only	abnormality.	
Most	 of	 the	 above	 developmental	 defects	 are	 also	 observed	 in	
p63	 knockout	 mice,	 which	 have	 particular	 severe	 defects	 of	 ecto-
dermal	 structures	 and	 the	 limbs.1,2	 Heterozygous	 p63+/-	 mouse	
have	 no	 significant	 developmental	 abnormalities,	 suggesting	 that	
loss-of-function	of	one	allele	 is	not	disease-causing.	Recently,	 it	has	










and	type	of	 the	ectodermal	 features	 is	highly	variable,	and	to	some	
extent	dependent	on	 the	exact	nature	of	 the	mutation	 (see	below).	
Only	 few	 patients	 show	 defects	 in	 all	 of	 the	 described	 ectodermal	
structures	 above.	 EEC	 patients	 occasionally	 also	 have	 mammary	





binding	 domain	 (DBD)	 of	 the	 p63	 gene	 (Table	 1).	 Altogether	 34	
different	mutations	have	been	reported,	and	20	different	amino	acids	




R304	 in	 the	 EEC	 population,	 all	 located	 in	 CpG	 islands	 (Fig.	 2).	





EEC	 mutations	 have	 a	 dominant	 negative	 effect.	 However,	 recent	
genotype-phenotype	analyses	for	the	five	hotspot	mutations	revealed	
significant	 differences	 between	 the	 corresponding	 phenotypes.	 For	
instance	 cleft	 lip/palate	 is	 present	 in	 the	 R304	 mutation	 popula-





that	 these	 hotspot	 mutations	 exert	 specific	 effects.	 Such	 specificity	
might	be	brought	 about	by	different	 effects	 of	 these	mutations	 on	
promoters	 for	 p63	 transcriptional	 target	 genes.	 Alternatively,	 these	
hotspot	mutations	may	exhibit	gain-of-function	effects,	similar	as	for	
the	p53	hotspot	mutations.13
Limb mammary syndrome (LMS).	The	LMS	phenotype	resembles	
the	EEC	syndrome	phenotype,	but	the	ectodermal	manifestations	are	
milder	(Fig.	1).3	A	consistent	feature	of	LMS	is	the	mammary	gland	










specific	 putative	 transactivation	 domain	 (TA2).3,12,14,15	 One	 other	
point	mutation	(S90W)	is	also	located	between	the	TA	domain	and	
DBD.	Other	LMS	mutations	are	reported	in	the	C-terminus:	a	TT	








to	 LMS	 syndrome,	 although	 clear	 differences	 can	 be	 seen	 when	
Figure 1. Various combinations of ectodermal dysplasia, orofacial clefting 
and limb malformations are the hallmark of p63-associated syndromes. EEC 
syndrome is the prototype of these syndromes and together with LMS shows 
all three hallmarks. ADULT syndrome patients never show orofacial clefting, 
whereas AEC and RHS never show limb defects. Non-syndromic limb defect 
condition (SHFM4) and non-syndromic cleft lip/palate (NSCL) are also 
caused by mutations in the p63 gene.
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affect	 DNA	 binding.21	 Instead,	 earlier	 studies	 have	 shown	 a	 gain-
of-function	 effect	 for	 the	mutated	DNp63g	 isoform,	which	usually	
does	not	have	a	transactivation	activity	in	assays	using	an	optimized	
p53-responsive	element.17,21	Two	other	mutations	are	located	in	the	




other	 conditions	mainly	by	 the	 severity	of	 the	 skin	phenotype,	 the	
occurrence	of	an	eyelid	fusion	at	birth	and	the	absence	of	limb	malfor-
mations	(Fig.	1).	Approximately	80%	of	the	patients	have	severe	skin	
erosion	at	birth,	which	usually	will	 recover	 in	 the	 first	years	of	 the	
life.	 The	 eyelid	 fusion,	 also	 called	 ankyloblepharon,	 is	 present	 in	
about	45%	of	AEC	patients,	but	only	rarely	in	other	p63-associated	
conditions.	The	other	ED	symptoms,	such	as	nail	and	teeth	defects	
are	present	 in	more	 than	80%	of	patients,	 and	hair	defects	 and/or	
alopecia	are	almost	constant	features	(94%).	Lacrimal	duct	obstruc-
tion	is	seen	in	50%	of	patients,	whereas	mammary	gland	hypoplasia	
and	 hypohydrosis	 occur	 occasionally	 (both	 13%).	 Interestingly,	
almost	40%	of	patients	have	hearing	impairment	and	genito-urinary	




(Fig.	 1).	The	 differences	 discussed	 earlier	 in	 several	 papers	 are	 the	
absence	of	ankyloblepharon	in	RHS	and	the	more	severe	skin	pheno-
type	in	AEC.11,24	Other	ED	symptoms,	such	as	orofacial	clefting	and	









tions	 in	 the	SAM	domain	or	deletions	 in	 the	SAM	or	TI	domains	
(Table	1).7,11,12,24-35	The	SAM	domain	is	known	to	be	involved	in	
protein-protein	interactions	and	therefore	mutations	in	this	domain	
are	 most	 probably	 hampering	 the	 binding	 to	 interacting	 proteins.	
One	 known	 interactor	 of	 p63	 SAM	 domain	 is	 the	 Apobec-1-
binding	protein-1	(ABBP1),	which	is	a	member	of	RNA	processing	
machinery	 and	 known	 to	 regulate	 the	 alternative	 splicing	 of	 the	
Fibroblast-growth-factor-receptor-2	 (FGFR2)	 towards	 the	 epithe-
lial	 specific	 isoform.	 AEC	 mutations	 in	 the	 SAM	 domain	 abolish	
the	 binding	 to	 ABBP1,	 which	 most	 probably	 leads	 to	 changes	 in	
FGFR2	 RNA	 splicing.36	 Interestingly,	 gain-of-function	 mutation	
Figure 2. Pathogenic p63 mutations cause at least five different syndromes and two non-syndromic conditions. Mutations causing different diseases are 
illustrated in different colours. Only mutations that are discussed in the text are indicated, an overview of all mutations is given in Table 1. EEC hotspot 
mutations are clustered in DNA binding domain, and RHS and AEC syndrome mutations in SAM and TI domains. Several mutations, such as R280, R313, 
I510, S541 and 1850 Del A, can have a variable clinical outcome, probably due to genetic background effects. The black asterisks illustrate sites needed 
for upiquitination (K193, K194 and PY) and the white asterisk represents a sumoylation site (fKXD/E).40,42,58
 
*In the article incorrect amino acid annotation, erratum pending ref. Slavotinek
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in	FGFR2	gene	have	been	reported	in	a	number	of	craniosynostosis	
syndromes,	 which	 are	 also	 characterized	 by	 distal	 limb	 malforma-









orofacial	 clefting	 or	 ectodermal	 dysplasia.	 The	 non-syndromic	
SHFM4	 is	 caused	 by	 several	 mutations,	 which	 are	 dispersed	
throughout	 the	 p63	 gene:	 a	 point	 mutation	 in	 the	 transactivation	
domain	(TA)	(R58C),	a	splice-site	mutation	in	front	of	exon	4	(3’ss	




several	 SHFM4	 mutations	 are	 reported	 to	 cause	 alteration	 in	 the	
p63	protein	activation	and	stability:	Q634X	and	E639X	are	known	
to	disrupt	 the	 sumoylation	 site,	 and	 therefore	 increase	 the	 stability	
and	transcriptional	activity	of	 the	p63a	 isoform.40,41	Furthermore,	
amino	acids	K193	and	K194	are	required	for	ubiquitin	conjugation	
by	E3	ubiquitin	 ligase	 (Itch)	 and	naturally	 occurring	mutations	 in	
those	amino	acids	cause	more	stable	p63	protein.42	Possibly,	SHFM	









causing	 the	 non-syndromic	 cleft	 lip/palate	 (NSCL)	 phenotype	 in	
the	p63	gene.8	This	mutation	was	also	observed	in	a	sporadic	EEC	
syndrome	phenotype	(authors’	unpublished	data).	Mutations	and/or	





or	were	 also	 found	 in	one	of	 the	healthy	parents	or	 in	 the	 control	
population,	 they	 were	 not	 considered	 to	 be	 pathogenic	 changes.	
Nevertheless,	since	orofacial	clefts	are	considered	to	have	a	multifac-
torial	origin	 it	 is	quite	possible	 that	 these	 changes	 in	 the	p63	 gene	






mutations	 are	 clustered	 in	 the	 DNA	 binding	 domain	 and	 in	 the	
SAM	 and	TI	 domains,	 respectively.	 In	 about	 250	 patients	 we	 and	
others	 have	 described	 74	 different	 mutations	 causing	 five	 different	
syndromes	 and	 two	 different	 non-syndromic	 conditions.	This	 still	
increasing	number	of	patients	allows	 the	delineation	of	 the	pheno-
typic	and	genotypic	pictures	of	different	p63-associated	disorders.	In	
addition,	 evidence	 is	 accumulating	 that	other	genetic	 factors	 influ-
ence	the	final	p63	mutant	phenotype.	
Several	 examples	 show	 that	 the	 same	 mutation	 can	 lead	 to	
different	 clinical	 conditions.	 AEC	 and	 RHS	 syndromes	 share	 three	




and	 ADULT	 syndrome	 seem	 to	 be	 caused	 by	 the	 same	 mutation	
G134D	(authors’	unpublished	data),23	as	well	as	EEC	syndrome	and	
non-syndromic	cleft	lip/palate	due	to	the	R313G	mutation	(authors’	
unpublished	 data).8	 Also	 several	 frameshift	 mutations	 are	 found,	




effects	 of	 modifier	 genes.	 An	 example	 of	 family-dependent	 clinical	
phenotype	 is	 the	arginine	280	mutation,	which	can	be	mutated	 to	
cysteine	or	histidine	and	lead	either	to	the	non-syndromic	SHFM4	
(2	 families)	 or	more	often	 to	 syndromic	 ectodermal	dysplasia	with	
SHFM	and	orofacial	clefting	(EEC)	(9	families).5,6,26,50	Surprisingly,	
the	penetrance	is	reduced	in	SHFM	families,	but	not	in	EEC	fami-
lies,	 which	 also	 indicates	 a	 modifier	 effect	 somewhere	 else	 in	 the	
genome.	
The	 phenotypic	 variation	 between	 the	 p63-linked	 diseases	 is	
large,	furthermore	the	phenotypic	variation	within	one	disease	is	also	
considerable.	It	is	clear	that	variability	within	families	may	be	ascribed	
to	 a	 combination	 of	 modifier	 genes,	 and	 stochastic	 processes.	 No	
such	modifier	genes	have	yet	been	identified	for	the	p63	syndromes	








downstream	 effects	 for	 each	 of	 these	 mutations.	 There	 are	 many	




mutations	 is	 also	 striking.	The	EEC	hotspot	mutation	data,	where	









different	 phenotypes	 between	 families,	 but	 the	 same	 phenotype	
consistently	within	families	suggest	the	influence	of	cis-acting	poly-
morphisms,	 either	 in	p63	 itself	 or	within	 a	 genetically	 linked	gene	
on	 chromosome	 3q.	 Such	 functional	 polymorphisms	 have	 not	 yet	
been	described,	but	here	too,	 there	are	precedents	 for	 the	existence	
of	 such	 polymorphisms	 in	 both	 p53	 and	 p73.56,57	 Each	 of	 these	
p63-Associated	Disorders
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possible	mechanisms	 for	 phenotypic	modulation	will	 require	 func-
tional	hypotheses	 that	can	be	verified	 in	experimental	 systems,	and	
ultimately	be	 tested	 for	 their	 impact	on	 the	many	 families	 that	are	
affected	by	these	clinically	often	severe	malformations.
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